CLINICAL TRIALS PROFILE FOR IMFINZI

All Clinical Trials for IMFINZI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01993810 ↗	Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer	Recruiting	National Cancer Institute (NCI)	Phase 3	2014-02-03	This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.
NCT01993810 ↗	Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer	Recruiting	NRG Oncology	Phase 3	2014-02-03	This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.
NCT01993810 ↗	Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer	Recruiting	Radiation Therapy Oncology Group	Phase 3	2014-02-03	This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.
NCT02154490 ↗	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	Active, not recruiting	National Cancer Institute (NCI)		2014-06-16	This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
NCT02154490 ↗	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	Active, not recruiting	Southwest Oncology Group		2014-06-16	This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
NCT02281084 ↗	Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes	Active, not recruiting	Celgene	Phase 2	2015-07-06	Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason for removing the combination arm: Due to difficulties with dose-finding, the durvalumab plus CC-486 combination arm was closed to enrollment. Extension: An Extension Phase (EP) has been added to allow subjects who are currently receiving oral azacitidine BID and who are demonstrating clinical benefit as assessed by the Investigator, to continue receiving oral azacitidine until the subject meets the criteria for study discontinuation.
NCT02281084 ↗	Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes	Active, not recruiting	Celgene Corporation	Phase 2	2015-07-06	Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason for removing the combination arm: Due to difficulties with dose-finding, the durvalumab plus CC-486 combination arm was closed to enrollment. Extension: An Extension Phase (EP) has been added to allow subjects who are currently receiving oral azacitidine BID and who are demonstrating clinical benefit as assessed by the Investigator, to continue receiving oral azacitidine until the subject meets the criteria for study discontinuation.

Clinical Trial Conditions for IMFINZI

Condition Name

Condition Name for IMFINZI
Intervention	Trials
Stage III Lung Cancer AJCC v8	8
Stage IIIB Lung Cancer AJCC v8	8
Stage IIIA Lung Cancer AJCC v8	8
Hepatocellular Carcinoma	7

Condition MeSH

Condition MeSH for IMFINZI
Intervention	Trials
Lung Neoplasms	40
Carcinoma	36
Carcinoma, Non-Small-Cell Lung	33
Adenocarcinoma	14

Clinical Trial Locations for IMFINZI

Trials by Country

Trials by Country for IMFINZI
Location	Trials
United States	527
Canada	26
Australia	14
Italy	9
Netherlands	7

Trials by US State

Trials by US State for IMFINZI
Location	Trials
Texas	30
California	24
Illinois	22
New York	18
Missouri	17

Clinical Trial Progress for IMFINZI

Clinical Trial Phase

Clinical Trial Phase for IMFINZI
Clinical Trial Phase	Trials
PHASE1	1
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for IMFINZI
Clinical Trial Phase	Trials
Recruiting	65
Not yet recruiting	29
Active, not recruiting	17

Clinical Trial Sponsors for IMFINZI

Sponsor Name

Sponsor Name for IMFINZI
Sponsor	Trials
AstraZeneca	56
National Cancer Institute (NCI)	33
M.D. Anderson Cancer Center	8

Sponsor Type

Sponsor Type for IMFINZI
Sponsor	Trials
Other	136
Industry	79
NIH	34

Clinical Trials Update, Market Analysis, and Projection for IMFINZI (Durvalumab)

Last updated: November 10, 2025

---

Introduction

IMFINZI (durvalumab) is a monoclonal antibody immunotherapy developed by AstraZeneca, primarily targeting PD-L1 (programmed death-ligand 1). Since its initial approval, IMFINZI has established itself as a key player in the oncology space, particularly for lung cancer and bladder cancer. This report provides a comprehensive overview of recent clinical trials, current market positioning, and future projections, equipping industry stakeholders with crucial insights for strategic decision-making.

---

Clinical Trials Update

1. Lung Cancer Indications

IMFINZI received accelerated approval from the FDA in 2018 for unresectable Stage III non-small cell lung cancer (NSCLC) following chemoradiation based on the PACIFIC trial data. As of Q1 2023, multiple ongoing phase III trials continue to evaluate its efficacy and safety:

• PACIFIC-4/LUN 5: Assessing durvalumab in early-stage NSCLC post-surgery.
• AEGEAN (NCT03830866): Evaluating durvalumab plus chemotherapy as neoadjuvant therapy in resectable NSCLC.
• DURVAB-05: Investigating durvalumab as maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC).

Preliminary data indicate sustained efficacy with manageable safety profiles, affirming the drug's role in both locally advanced and metastatic settings.

2. Bladder and Urothelial Cancers

In March 2020, the FDA granted accelerated approval for IMFINZI for locally advanced or metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy, based on Phase I/II data. Ongoing trials such as DANUBE (NCT02516341) are evaluating durvalumab alone versus durvalumab combined with tremelimumab:

• DANUBE Trial Results (2022): Did not meet primary endpoints for improved overall survival compared to chemotherapy, but subgroup analyses suggest potential benefits in PD-L1 high expressers.

Further studies are underway to optimize its role, including combination therapies with agents like chemotherapy and targeted therapies.

3. Other Tumor Types

Durvalumab is under investigation in a variety of other indications:

• Head and Neck Squamous Cell Carcinoma (HNSCC): Several phase II trials are assessing efficacy post-chemoradiotherapy.
• Gastric and Gastroesophageal Junction Cancers: Trials like ARTEMIS-1 evaluate durvalumab with chemotherapy.
• Triple-Negative Breast Cancer (TNBC): Early-phase studies are exploring its combination potential with chemo.

The breadth of ongoing trials underscores AstraZeneca's commitment to expanding durvalumab’s oncology indications.

---

Market Analysis

1. Current Market Size and Revenue

IMFINZI garnered approximately $2.2 billion in global sales in 2022, reflecting robust demand driven by its approval in key lung and bladder indications ([1]). The North American region remains the largest market, attributed to high incidence rates and established reimbursement pathways. Emerging markets are beginning to contribute as regulatory approvals expand.

2. Competitive Landscape

Durvalumab faces competition primarily from:

• Pembrolizumab (Keytruda, Merck): Dominates in lung and bladder cancers, with broader indications and extensive clinical data.
• Atezolizumab (Tecentriq, Roche): Similar mechanisms, with significant market penetration.
• Avelumab (Bavencio, Merck): Approved for Merkel cell carcinoma and urothelial carcinoma.

While pembrolizumab holds a larger market share, durvalumab’s favorable safety profile and ongoing trial pipeline support its growth trajectory.

3. Market Expansion Opportunities

Key factors influencing market growth include:

• Regulatory approvals: Expanding indications, especially in earlier-stage cancers.
• Combination therapies: Synergistic regimens with chemotherapy, targeted agents, and radiotherapy.
• Biomarker-driven personalization: Utilizing PD-L1 expression levels to optimize patient selection.
• Geographic expansion: Growing presence in China and other emerging markets, aided by strategic partnerships.

4. Regulatory and Reimbursement Dynamics

In 2022, AstraZeneca expanded IMFINZI’s approvals across multiple jurisdictions, including the European Union and Japan. Reimbursement pathways are favorable in markets with established immunotherapy frameworks, although pricing negotiations remain critical, especially in cost-sensitive regions.

---

Market Projection

1. Forecast Overview (2023-2030)

The global immunotherapy market for lung and bladder cancers is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 9%, reaching an estimated $25 billion by 2030 ([2]). IMFINZI is expected to capture a significant share given its ongoing clinical development and expanding indications.

• 2023-2025: Market revenues are estimated to grow annually by 12-15%, driven by increased adoption, label expansions, and new trial approvals.
• 2026-2030: As further indications and combination options solidify, revenues could approximate $5-7 billion annually, making IMFINZI one of the leading PD-L1 inhibitors.

2. Strategic Drivers

• New Indication Approvals: Early pipeline success and supplemental approvals will propel growth.
• Biomarker-based Personalization: Tailoring treatments to PD-L1 expression levels will optimize patient outcomes and clinical uptake.
• Combination Therapy Efficacy: Demonstrated benefits in combination settings will notably expand usage.

3. Risks and Challenges

• Competitive Pressure: Pembrolizumab and atezolizumab continue to innovate and expand their indications.
• Trial Outcomes: Negative or inconclusive trial results could hinder expansion efforts.
• Pricing and Reimbursement Hurdles: Cost control measures may impact adoption rates, particularly in cost-sensitive health care economies.

---

Key Takeaways

• Robust Clinical Pipeline: Ongoing trials across diverse cancer types suggest sustained growth potential, especially for early-stage and combination therapies.
• Market Leadership Opportunity: While competing in a crowded PD-L1 space, IMFINZI’s safety profile and expanding label coverage position it for continued market share growth.
• Strategic Expansion: Key growth drivers include geographic expansion, biomarker-driven treatment personalization, and regulatory approvals for new indications.
• Revenue Growth Outlook: The immunotherapy segment’s projected CAGR indicates IMFINZI could generate up to $7 billion in annual revenue by 2030 if current trends persist.
• Competitive Dynamics: Innovation, trial success, and healthcare policy will determine its trajectory relative to peers.

---

FAQs

1. What are the primary approved indications for IMFINZI?
IMFINZI is approved for unresectable Stage III NSCLC after chemoradiation, extensive-stage small cell lung cancer (ES-SCLC), and locally advanced/metastatic urothelial carcinoma in eligible patients ([1]).

2. How does IMFINZI compare to other PD-L1 inhibitors?
IMFINZI offers a favorable safety profile and is currently competitive in efficacy. Its primary differentiators include ongoing trials exploring new combinations and indications, with some evidence suggesting improved tolerability.

3. What are the recent regulatory updates for IMFINZI?
In 2022 and 2023, AstraZeneca received approvals in the EU, Japan, and other markets for additional indications, including early-stage NSCLC and combination regimens ([1]).

4. Which ongoing clinical trials are most promising for IMFINZI?
Trials such as PACIFIC-4/LUN 5 and AEGEAN promise to expand IMFINZI’s role in earlier stages of lung cancer, potentially broadening its therapeutic footprint.

5. What are key risks facing IMFINZI's market growth?
Intense competition, mixed trial results in certain combinations, regulatory delays, and pricing pressures pose significant risks to sustaining market momentum.

---

References

[1] AstraZeneca. (2023). IMFINZI (Durvalumab) Prescribing Information.
[2] GlobalData. (2023). Immuno-Oncology Market Forecast Report.